INTRODUCTION
Myeloid malignancies offer an attractive model to test immunotherapeutic approaches in view of the striking evidence that immunological Graft-versus-Leukemia (GvL)-reactions efficiently eradicate malignant cells after transplant. We previously demonstrated that vaccination with one subcutaneous dose of two leukemia-associated antigens (LAA),
PR1
(2-5) and WT1 (5) (6) (7) (8) (9) (10) (11) peptides, in Montanide-adjuvant with granulocyte-macrophage colony-stimulating factor (GM-CSF) (study 06-H-0062), induced transient PR1 or WT1-specific CD8+ T-cells associated with a significant but short-lived reduction in minimal residual disease (MRD) (1) .
We hypothesized that maintenance of a sustained anti-leukemia response might require frequent boost injections and initiated a phase-2 study of repeated PR1 and WT1
peptide vaccination in patients with myeloid malignancies. We report here that CD8+ Tcell responses against PR1 or WT1 were induced in all patients. However, repeated vaccination led to selective deletion of high-avidity PR1 and WT1-specific CD8+ T-cells with preferential expansion of low-avidity responses, not associated with significant reductions in WT1-expression. These data may offer an explanation for the lack of correlation between immune and clinical responses reported in several clinical trials of peptide vaccination in cancer (12;13) . New vaccine approaches are needed to induce longterm high-avidity memory responses against tumor-antigens.
DESIGN AND METHODS

Clinical trial design
HLA-A*0201 positive patients with acute myeloid leukemia (AML) in remission and myelodysplastic syndromes (MDS) were recruited (Protocol #07-H-0159). Entry criteria included: age >18 years, bone marrow (BM) cellularity ≥20%, no corticosteroid treatment within 14 days prior to enrolment, negative serology for anti-proteinase-3 or anti- 
Assessment of toxicity
At each outpatient visit, patients were evaluated for toxicities according to the National Cancer Institute Common Toxicity Criteria and independently reviewed by the Data Safety Monitoring Board (DSMB). The protocol mandated discontinuation of vaccination in any one patient if grade ≥3 toxicity was observed.
Sample collection and storage
Peripheral blood mononuclear cells (PBMCs) and BM mononuclear cells (BMMNCs)
were separated using Ficoll-Hypaque density gradient centrifugation (Organon-Teknika, High-resolution HLA class-I genotyping was performed by sequence-specific polymerase chain reaction (PCR) using genomic DNA (HLA-Laboratory, NIH, Bethesda, MD).
Evaluation of immunogenicity with peptide-HLA class-I tetrameric complexes
Fresh PBMC obtained before and 2-weekly after vaccination and fresh BMMNC at week 
.
Functional evaluation of antigen-specific CD8+ T-cells
Intracellular-cytokine detection was performed as described previously. In brief, 10 6 fresh PBMC were resuspended in RPMI-CM supplemented with 10% human AB serum and incubated overnight at 37°C (humidity, 90%; CO 2 , 5%) to minimize background IFN-γ production secondary to lymphocyte manipulation during processing. The following day fresh PBMCs and BMMNCs were loaded with or without test peptides (0.1 and 10 µM).
After 2 hours, 10 µg/mL Brefeldin-A (Sigma) was added. After an additional 4 hours, 
Enumeration of Foxp3+CD4+ T-cells
For each patient, stored aliquots of PBMCs collected at different timepoints were thawed on the same day and phenotypically analyzed by 4-color flow cytometry using a titrated panel of directly conjugated antibodies to CD3, CD4 and CD25 (M-A251) (all Beckman
Coulter, Miami, FL). Intracellular analysis of FoxP3 (eBioscience, San Diego, CA) was performed after fixation and permeabilization according to the manufacturer's recommendation as described previously (14) . 
Short-term expansion of PR1-and WT1-specific CD8 + T-cells in vitro
Functional evaluation of CD8+ T-cells by IFN-γ ELISPOT assay
The frequency of antigen-specific T-cells in freshly thawed PBMCs and after 7-days in vitro expansion was assessed as described previously (15;16) . Briefly, anti-IFN-γ-coated (15) .
In 7-day expansion assays, the antigen-specific T-cell response was enhanced by supplementing culture media with IL-12 (2 ng/mL). replicate wells. Spots were counted using an automated ELISPOT-reader (AID, Strassberg, Germany) and the ELISPOT 3.1 SR software.
Measurement of WT1 by real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
All samples for qRT-PCR were blinded. RNA was isolated from a minimum of 10 6 PBMC using RNeasy mini-kits (Qiagen, CA, USA). cDNA was synthesized using the Advantage RT-for-PCR kit (Clontech, Mountain View, CA, USA). ABL expression was used as the endogenous cDNA quantity control for all samples (17) . All reactions by qRT-PCR using the ABI PRISM 7900 sequence detection system (Applied Biosystems, Foster City, CA, USA) were performed in triplicate using standard conditions with 40 cycles of amplification. WT1 qRT-PCR reactions could consistently detect one leukemic in 1000,000 non-leukemic cells (1) .
Results
Patient characteristics and summary of clinical toxicities
Eight HLA-A*0201 positive patients (2 MDS and 6 AML) were enrolled in this study and their clinical characteristics are presented in Table 1 
Vaccination induces transient PR1 and WT1-specific CD8+ T-cell responses
Fresh PBMC collected pre-and 2-weekly post-vaccination were analyzed directly ex- No patient had detectable PR1 or WT1-specific CD8+ T-cell responses (defined as a minimum of 0.05% IFN-γ+ CD8+ T-cells 5 ) at enrolment in the current study (Table 1) .
Patients 1-6 had previously received one dose of PR1 and WT1 peptides in NIH study
06-H-0062
(1) . The median interval between completion of participation in study 06-H-0062 and enrolment in the current Phase-2 study was 241 days (82-485). A significant PR1 or WT1-specific CD8+ T-cell response was detected as early as 2 weeks following the first vaccine dose in 7/7 evaluable patients, median for PR1 0.12% (0.06%-0.32%) and for WT1 0.10% (0.07%-0.19%). However further boosting failed to expand the vaccine-induced response and in 6/6 evaluable patients responses were no longer detectable by the 6th dose (Figure 1 ).
Repeated vaccination leads to preferential expansion of low-avidity,
PD-1 negative, PR1 and WT1-specific CD8+ T-cells
To determine the functional avidity of the vaccine-induced CD8+ T-cell response, we measured the response of CD8+ T-cells to stimulation with 2 concentrations of PR1 and WT1 peptides (0.1 and 10 µM) by IC-IFN-γ staining (19) . High and low-avidity T-cells possess different requirements for peptide/MHC density and CD8 interaction (19) . We defined high-avidity CD8+ T-cells as those capable of producing IFN-γ in response to a lower concentration of peptide (0.1 µM), while low-avidity CD8+ T-cells were those that produced IFN-γ in response to a higher concentration of peptide (10 µM To determine if programmed death-1 (PD-1), a negative regulator of T-cells (22) , impaired vaccine-induced T-cell expansion, we analyzed the expression of PD1 on the surface of PR1 and WT1/HLA-A*0201 tetramer-binding CD8+ T-cells in 3 patients but found no evidence of PD1 upregulation (data not shown).
All patients who completed 6 courses of vaccine (patients 1, 2, 3, 4, 6 and 7) returned 3 months following the 6th dose for repeat blood tests. By ex-vivo peptide/HLA-A*0201
tetramer and intracellular-IFN-γ assays, PR1 and WT1-specific CD8+ T-cells were not detected in the PB of 6/6 evaluable patients 3 months following the 6th vaccine dose. To determine if low frequencies of CD8+ T-cells against PR1 and WT1 could be detected by short-term expansion, PBMC from patients 4, 6 and 7 were stimulated with PR1 and WT1 peptides in a 7-day cultured Elispot assay. PR1 and WT1-specific CD8+ T-cells failed to expand, although culture conditions allowed expansion of CMV-specific CD8+
T-cells from the same patients (data not shown). They proposed that the sustained systemic presentation of the peptides gradually leaking out of the oil-in-water depot without systemic danger signals leads to tolerance induction. This hypothesis was further supported by the demonstration that vaccination with peptides admixed with PBS, resulting in relatively short duration of antigen presentation, induced memory CD8+ T-cells that were able to expand upon secondary antigen stimulation in vitro. Interestingly, a recent report has also questioned the value of GM-CSF as a vaccine adjuvant (29) . Furthermore the route of application, dose and dosing interval of the adjuvant may be critical in determining the immunological effect.
Several trials using lower doses of GM-CSF have reported improvement in vaccineinduced CTL responses, whereas trials employing higher doses of GM-CSF have shown no effect or even a suppressive effect.
The ability of vaccine-induced CD8+ T-cells to mediate in vivo anti-leukemia cytotoxicity was assessed indirectly by correlating the kinetics and avidity of PR1 and WT1-specific CD8+ T-cells with WT1 expression in PB. To study the functional avidity of the CD8+ Tcell response against individual PR1 and WT1 epitopes, CD8+ T-cell were stimulated with increasing peptide concentrations; an arbitrary "functional avidity ratio" was calculated based on these readouts. In 2 patients, vaccination induced transient high-avidity PR1 or WT1-specific CD8+ T-cells that coincided with significant, albeit shortlived, reduction of WT1 expression. WT1 has been shown to be a reliable marker of MRD in myeloid malignancies (30) (31) (32) (33) (34) . In the remaining patients, induction of low-avidity CD8+ T-cells to PR1 or WT1 was not associated with a significant reduction in MRD.
Several studies have shown that high-avidity CTLs are essential for effector anti-tumor responses (35) (36) (37) . Although due to limitations in patient samples we were unable to directly demonstrate the cytotoxicity of high avidity vaccine-induced CD8+ T-cells against leukemic blasts, the association of high-avidity CD8+ T-cells and anti-leukemia antigen, were induced to undergo apoptosis when stimulated with high-dose peptide antigen in vitro, (39) suggesting that a high viral load might lead to clonal deletion of highavidity HIV-specific CTLs over time. Similarly, it was shown that high-avidity PR1-CTLs die by apoptosis when exposed to either high-dose peptide antigen or to leukemia cells that overexpresse proteinase 3 (20) . A recent trial of peptide vaccination in patients with melanoma in CR reported that following boosting, the vaccine-induced CD8+ T-cells failed to acquire enhanced functional avidity usually associated with competent memory T-cell maturation (38) . We assessed the quality of the vaccine-induced CD8+ T-cell response by comparing the relative frequencies of high and low-avidity PR1 and WT1-specific CD8+ T-cells. In our Phase 1 study, while both high and low-avidity PR1 and WT1 specific CD8+ T-cells were elicited following a single dose of PR1 and WT1 peptide vaccines (1) , only low-avidity PR1 or WT1-specific CD8+ T-cells could be expanded following repeated vaccination. The selective deletion of high-avidity leukemia-specific CTLs has been shown to be an escape mechanism from tumor immunity. placebo-treated controls (40) . Although, it is conceivable that if sufficient numbers of low-avidity vaccine-specific T cells are elicited, adequate anti-leukemia activity might still be possible.
The transient immunological and clinical responses seen here and in other trials of peptide vaccination with CD8 epitopes may be partly explained by the lack of CD4+ Tcell help. While CD4+ T cells are dispensable for primary expansion of CD8+ T cells and their differentiation into cytotoxic effectors, secondary CTL expansion is wholly dependent on the presence of CD4+ T-cell (41) . In a number of animal studies, vaccination with CD8+ and CD4+ T-cell epitopes has been shown to result in long-term CD8+ T-cell immunity (28); (42;43) . Indeed, in a humanized murine model, vaccination with WT1 CD8 epitopes fused to the fragment C (FrC) of tetanus toxin to provide CD4+ Tcell help and delivered via DNA was superior to exogenous peptide plus IFA. 
It is likely that the efficacy of peptide vaccination depends on the balance between effector and regulatory T-cells (T regs ). Experimental murine models and human vaccine studies have demonstrated that T reg depletion contributes to durable protective antitumor immunity. (46) (47) (48) We noted a significant and transient reduction of circulating CD4+Foxp3+ T-cells within the CD4+CD25+ T-compartment, suggesting a selective loss of regulatory T cells over the course of the vaccination period. This was concomitant with the vaccine-induced CD8+ T-cell response. However, T reg frequencies returned to baseline by the 6 th vaccine dose. Similarly other groups have reported significant reduction in T regs (antigen-specific and non-specific) following vaccination (49;50) . T regs appear to be highly sensitive to CD95L-induced apoptosis, in contrast to their more resistant T eff counterparts. (51;52) In vivo, the apparent selective sensitivity of T reg to CD95L might be a mechanism to eliminate T reg during the acute effector phase of an immune response at a time when T eff are resistant to CD95-mediated apoptosis. This may partly explain our observation that the FOXP3-positive compartment of CD4+CD25+ T-cells was selectively depleted. It is therefore possible that systemic depletion of T reg may further enhance the immune response to vaccination (53) (54) (55) .
In summary these data raise important questions regarding the validity of vaccination with self-antigen derived short peptides and may offer an explanation for the lack of correlation between immune and clinical responses reported in a number of clinical trials (12;13) . These results call for a re-evaluation of the current strategies of vaccination in patients with hematological malignancies and cancer in general, especially since peptide weeks post-vaccine.
